Clinical Trials Using Pleiotropic Pathway Modifier CC-122 Hydrochloride
Clinical trials are research studies that involve people. The clinical trials on this list are studying Pleiotropic Pathway Modifier CC-122 Hydrochloride. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Avadomide and Nivolumab in Treating Patients with Unresectable or Metastatic Melanoma
This phase II trial studies how well avadomide and nivolumab work in treating patients with melanoma that cannot be removed by surgery or has spread to other places in the body. Avadomide is a “pleiotropic pathway modulator” that may affect cancer in many ways. Pleiotropy refers to a case where one target may influence several other characteristics or may have multiple effects in numerous tissues such as tumor, blood vessels, and cells of the immune system. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving avadomide and nivolumab may work better in treating patients with melanoma compared to nivolumab alone.
Location: Moffitt Cancer Center, Tampa, Florida